The potential reclassification of cannabinoids, particularly at the federal level, is generating considerable anticipation within the market. A shift away from Schedule I status, often regarded as outdated and hindering advancement, could unlock significant avenues for companies. Reduced regulatory impediments, alongside greater access to banking a